Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. - Wikidata - awgldk - TriplyDB

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.

http://www.wikidata.org/entity/Q34529725

about

Recent advances in the medical treatment of breast cancer Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo Surveillance Mammography in Older Patients With Breast Cancer-Can We Ever Stop?: A Review.Major clinical research advances in gynecologic cancer in 2016: 10-year special edition.How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention?Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials.The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program "CASCADE".Oncology providers' perspectives on endocrine therapy prescribing and management.Are another 5 years of adjuvant aromatase inhibitor therapy needed?ASCO 2016: highlights in breast cancer.Clinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast Cancer Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG MR imaging features associated with distant metastasis-free survival of patients with invasive breast cancer: a case-control study.Extended Adjuvant Endocrine Therapy in Hormone Receptor-Positive Early Breast Cancer.Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer.Highlights of the San Antonio Breast Cancer Symposium 2016.Extended adjuvant endocrine therapy in early breast cancer: a meta-analysis of published randomized trials.Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients.Long-Term Follow-Up of the Intergroup Exemestane Study.Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours-a review.Digestive Disease Week And American Society of Clinical Oncology.Extended Endocrine Therapy: Is 5 Years Enough?Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer.Second Opinions From Medical Oncologists for Early-Stage Breast Cancer: Prevalence, Correlates, and Consequences.Weight changes in postmenopausal breast cancer survivors over 2 years of endocrine therapy: a retrospective chart review.Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting.Breast cancer treatment-induced cardiotoxicity.Acute acalculous cholecystitis due to breast cancer metastasis to the cystic duct.Loss of steroid hormone receptors is common in malignant pleural and peritoneal effusions of breast cancer patients treated with endocrine therapy.ER-positive breast cancer patients with more than three positive nodes or grade 3 tumors are at high risk of late recurrence after 5-year adjuvant endocrine therapy.Estrogens - the Saviors of Cognitive Function?CYP19A1 gene polymorphism and colorectal cancer etiology in Saudi population: case-control study.20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.Identifying socio-demographic and clinical characteristics associated with medication beliefs about aromatase inhibitors among postmenopausal women with breast cancer.Letrozole-induced hepatitis with autoimmune features: a rare adverse drug reaction with review of the relevant literature.Endocrine Therapy for Early Breast Cancer: Updated Review.Weight gain in hormone receptor-positive (HR+) early-stage breast cancer: is it menopausal status or something else?Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years.Fractures in a nationwide population-based cohort of users of breast cancer hormonal therapy.Utility of molecular tools for extended adjuvant endocrine therapy decisions in early breast cancer.

P2860

Q28078951-EC6A8B0F-92F7-48CD-BB0D-13A1E39F7BB1 Q30275126-BD61CC54-8088-49D1-9A70-2E8ED2C1B423 Q30395721-9E998293-201C-4A2E-9917-8DE13777C7D4 Q33563963-9138D66C-E5DE-4591-8770-0EB5C6589053 Q33767120-63B9F5BF-DD0B-4534-B73E-BAF882567633 Q36229869-8CE481B6-80FE-4E3A-A377-F1474F0A7881 Q36233893-E96A2E7E-8733-4727-8991-057C09AAC89C Q37316792-3DF179BA-F646-498D-B2B2-71451E337DCF Q37426725-AB629C22-9751-4787-85B9-94018E0FFAAF Q37512196-BDAC4893-F155-4F6B-92A9-950EC3C0772E Q37699590-C010D7F0-9C74-46FB-9D6D-F824137688B2 Q37742180-A640A1B3-2FDA-4820-A53D-9DEADB47014B Q38405899-128CEEE3-BDDC-4317-90BE-7EE0AAC126D8 Q38635960-81777A0B-0113-4FEF-B6CB-E70D4F0D109A Q38648577-30014478-55A1-486F-82D3-095D788A47A6 Q38666679-04A3F6A2-E954-44E6-95FC-A0B6049F9B2F Q38722951-E7EDFA5A-62D3-4CE3-8F02-4BC38AB8AD9A Q38737784-50FECE30-0195-4F87-AA56-86585971473E Q38806937-E80585C4-5431-4CF5-8071-CD54140F36C7 Q38842674-ABD8375D-70B0-4C99-A8D4-5CCE0D0B3AD8 Q38894889-AF8B4C07-88A9-4BF4-B59A-D5BB5C9AC44E Q38934318-E332DA74-17EF-41E2-9608-B1188D757E5E Q38968531-D7343D62-3C27-4B1C-A322-CE2527ABC4C7 Q39053012-3DE2B901-8BA0-4F43-AFE8-E9BA7E8C62B8 Q39117032-81D64DF5-5ED5-4C01-90E0-B3755D28845A Q39315948-9FC0970E-870C-4C2C-B2DC-FC9A7831A55C Q39428826-184BF1C6-749B-4D77-BF13-62861D6604A5 Q41428228-C9E9C7D0-EB95-452C-B708-0AC5BF0AE5C6 Q41547969-D2A493EF-3222-4773-8754-7421DBEACA54 Q42373183-B2169BBC-162E-4F93-8818-5EA821ED09C9 Q42390025-D85BC73E-B9BE-4261-94A7-41082DD3EC4D Q42736011-473FBFAA-8B0D-4465-93FC-D037F1758218 Q43006981-6A14D982-0264-4BDB-9602-F5BC15ED1AE7 Q45053792-3F2C0DC1-CE66-4E30-B2E7-EE8861D38B63 Q47099380-56BDBEC6-A37C-40AF-ADA1-7340C74E7CD9 Q47161589-2864BF0B-FEC5-4C94-A55A-BED2A867E7AF Q47187808-34DC8912-20AC-48AB-BA43-E3AA930C0694 Q47556532-BA4F8E51-662F-4A16-991A-3BA17B42A053 Q47575598-75076969-14A1-487B-8538-40E9B4DE28AF Q47821919-0D027C73-3B82-48E0-9C2B-3D71ADE6609C

P2860

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.

http://www.wikidata.org/entity/Q34529725

description

2016 nî lūn-bûn

@nan

2016 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.

@ast

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.

@en

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.

@nl

type

label

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.

@ast

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.

@en

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.

@nl

prefLabel

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.

@ast

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.

@en

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.

@nl

P1433

Q34529725-EAC99990-1341-4B8F-8967-3A95F1C240E8

P1476

Q34529725-D8CA73EA-C4D2-415A-B022-0E47CDAE9853

P2093

Q34529725-011290BD-D947-424E-BFFA-D285C645135A

Q34529725-04E069C0-3046-468F-A68E-9C746998EA66

Q34529725-0E9FB7E3-36B2-45CD-94AA-1A2FDD92FEFC

Q34529725-27399A4B-9D65-4C36-A735-667030E03760

Q34529725-29031D4A-0D2A-4493-A6E1-8A57CB59D6A5

Q34529725-296E64DF-8125-43EF-AAAF-184AE86F9CCF

Q34529725-2B511CFE-4EC9-449F-A3E9-494E121D5C83

Q34529725-422D3666-0CD4-42D7-85F0-568518F9077A

Q34529725-4CE187D6-7920-40FD-880A-7B81376082D5

Q34529725-716D84C4-55C0-4E94-99B1-82B4A4F3613C

P2860

Q34529725-05020F29-679D-43F0-92F1-3E1565336C98

Q34529725-12780E44-A404-4676-B7C9-29ECCCA4572B

Q34529725-2CAA19B4-1EE1-4C16-B274-E1B9CD4E2FA3

Q34529725-531FA3FC-C8DA-4C42-81E6-1FAD0FF7C2F1

Q34529725-538D634B-AE82-47E6-911C-C5ACBBC04306

Q34529725-6E77295C-696C-4A6E-A93A-9D40C9A54BFC

Q34529725-7829AD64-E127-49CF-9007-5A128CF91FE0

Q34529725-A46F4707-9A5B-4EE2-B59E-2E6A7E914FD8

Q34529725-B32B04B5-B64F-4497-931F-DABAB67D8637

Q34529725-D31DEF29-60BC-4260-957B-AA6929FFB527

P304

Q34529725-5331945F-91BD-4EEB-A938-7002F575604D

P31

Q34529725-04214BAC-5874-4BC1-9715-9981BFA3B9FB

P356

Q34529725-1C935A10-204B-4AF7-80ED-D8BD635D0491

P407

Q34529725-E2C1091D-0A26-44EA-B652-E282370E4158

P433

Q34529725-36BD119E-465C-4E1D-8591-A90DA79441FF

P478

Q34529725-67B7AF14-6F1B-4BCE-A79C-9DF61C47A396

P50

Q34529725-508EC937-53D8-4848-994E-4D3BDE08A417

Q34529725-63F2F12F-49E0-448D-BF22-10098E4654CD

P577

Q34529725-584B0036-2173-4DDB-9807-C10A24F781B4

P698

Q34529725-F5DF8E80-F17F-4B05-8A97-8F35920743C0

P932

Q34529725-9E1CD7B6-9911-4FC1-8CCF-CE358A21BCD3

P356

P1433

The New England Journal of Medicine

P1476

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.

@en

P2093

Alison Stopeck

http://www.w3.org/2001/XMLSchema#string

Clifford Hudis

http://www.w3.org/2001/XMLSchema#string

Dongsheng Tu

http://www.w3.org/2001/XMLSchema#string

Eric Winer

http://www.w3.org/2001/XMLSchema#string

Hyman Muss

http://www.w3.org/2001/XMLSchema#string

J Thaddeus Beck

http://www.w3.org/2001/XMLSchema#string

James N Ingle

http://www.w3.org/2001/XMLSchema#string

Judith S Kaur

http://www.w3.org/2001/XMLSchema#string

Julie Gralow

http://www.w3.org/2001/XMLSchema#string

Karen Gelmon

http://www.w3.org/2001/XMLSchema#string

P2860

The MOS 36-ltem Short-Form Health Survey (SF-36)

Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation.

Tamoxifen for early breast cancer.

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

Extended adjuvant endocrine therapy in hormone-receptor positive breast cancer.

Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer.

Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer.

A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.

Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer.

A menopause-specific quality of life questionnaire: development and psychometric properties.

P304

209-219

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1604700

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

375

http://www.w3.org/2001/XMLSchema#string

P50

Antonio C. Wolff

Kathrin Strasser-Weippl

P577

2016-06-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27264120

http://www.w3.org/2001/XMLSchema#string

P932

5024713

http://www.w3.org/2001/XMLSchema#string